An observational study in Cerebral Small Vessel Diseases and Ischemic Stroke, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital — 6 open to participants now, 7 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · Beijing Tiantan Hospital.
Among the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, this one is one of 2 that started in 2023, is one of 3 observational ones, and was the 5th registered.
128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.
Browse Cerebral Small Vessel Diseases studies →6 of the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 45–80
Beijing Tiantan Hospital · Sites in China
Ages 50–75 · Healthy volunteers
Beijing Tiantan Hospital
Ages 30+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 35–75
By country, each count listing its studies:
Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 260 across 56 observational studies indexed under Cerebral Small Vessel Diseases.
Median enrollment 328 across the 7 interventional studies, 3,500 across the 3 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
2 of the studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07252544Phase 3Beijing Tiantan HospitalIsosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT) | 2027-08-31 |
| NCT06512376Beijing Tiantan HospitalHereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort | 2027-07-19 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in different types of cerebral small vessel disease and iachemic stroke, as well as their pathogenesis, severity, and prognosis; And to research on the drug treatment of microcirculatory disorders for cerebral small vessel disease and stroke in the real world.
Cerebral small vessel disease (CSVD) is a clinical syndrome with imaging and pathological changes, which is caused by various structural abnormality or functional dysfunction of small blood vessels including cerebral arterioles, perforating arteries, capillaries, and venules. It is also a common cause of stroke. Among people over 60 years old, the prevalence of CSVD exceeds 80%, and it is speculated that the number of CSVD patients in China exceeds 200 million, far higher than the number of stroke patients. CSVD can cause about 20% of stroke and 50% of dementia, while also doubling the risk of dementia and death, and tripling the risk of stroke. It is an important cause of death and disability in elderly people in China.
Stroke is a kind of cerebrovascular diseases characterized by sudden localized or diffuse neurological deficits caused by cerebral blood circulation disorders, and is the main clinical phenotype of cerebrovascular diseases. Stroke is characterized by high incidence rate, high disability rate, high mortality, high recurrence rate, and high economic burden. It is the first cause of death and disability in adult in China.
Microcirculatory disorders may play an important role in the pathophysiological process of ischemic CSVD. The pathological process of CSVD involves various components of the neurovascular units, including the blood-brain barrier composed of vascular endothelial cells, basement membrane, pericytes, and astrocytes, as well as oligodendrocytes, neurons, and extracellular matrix, etc.Among them, the disruption of the blood-brain barrier and endothelial damage are considered to be the initial stage of the pathological process of CSVD, causing the destruction of various secondary microcirculation structures and functions, namely the occurrence of microcirculatory disorders.
Microcirculatory disorders may also play a major role in the occurrence and development of ischemic cerebrovascular disease. By exploring multiple omics markers such as specific molecular biological markers related to ischemic cerebrovascular disease in the pathophysiological pathways of microcirculatory disorders, traditional risk factors and imaging markers can be combined to create prediction models for ineffective reperfusion of acute ischemic stroke and progression of CSVD, providing scientific evidence for improving the prognosis of acute ischemic stroke and CSVD.
Study 1: Patients with acute ischemic stroke.
Study 2: Patients with ischemic stroke during the recovery period.
Study 3: Patients with cerebral small vessel disease based on STRIVE classification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study 1:
Study 2:
Study 3:
Within 3 years, there are characteristic lesions of cerebral small vessel disease on head MRI or CT, and they meet at least one of the following criteria:
Exclusion Criteria:
Study 1:
Study 2:
Study 3:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Establish a Chinese registry platform for microcirculatory disorders after acute ischemic stroke; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders after acute ischemic stroke.
Establish a national registry platform for microcirculatory disorders in ischemic stroke during recovery period; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders in ischemic stroke during recovery period.
Establish a national registry platform for microcirculatory disorders in CSVD; use this registry platform to record the prevalence, diagnosis and treatment information, and disease outcome of microcirculatory disorders in CSVD.
The correlation between microcirculatory disorders and recurrence of stroke (ischemic stroke and hemorrhagic stroke)
This study will collect disease information related to microcirculatory disorders and recurrent stroke among patients with acute ischemic stroke.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
Correlation between microcirculatory disorders and daily living ability levels (mRS) in patients with acute ischemic stroke
This study will collect disease information related to microcirculatory disorders and mRS among ischemic stroke patients during recovery period.
Time frame: baseline, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and cognitive function in CSVD (Mini COG).
This study will collect disease information related to microcirculatory disorders and Mini COG among patients with CSVD.
Time frame: baseline, 3th month, 12th month
The drug treatment of acute ischemic stroke in the real world based on microcirculation disorders.
Record all the medication treatment information during the follow-up period since the last visit, and all the medications information is collated to describe the patient's medication regimen.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the combination of vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death) in the recovery period of ischemic stroke.
This study will collect Major Adverse Cardiovascular Events (MACE): including ischemic stroke, hemorrhagic stroke, myocardial infarction, and vascular death.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the pathogenesis of acute ischemic stroke with different etiological subtypes.
Record the final diagnosis and main combined diagnosis of this enrollment event and complete blood laboratory examination, transcranial doppler ultrasound examination, physical examination and the like to ensure and evaluate the correlation between microcirculatory disorders and the pathogenesis of recovery ischemic stroke in different etiological subtypes.
Time frame: baseline, 3rd month, 12th month
The correlation between microcirculation disorders and the severity of acute ischemic stroke.
This study will collect disease information related to microcirculatory disorders among patients with acute ischemic stroke to evaluate the correlation between microcirculation disorders and the severity of acute ischemic stroke.
Time frame: baseline, 3rd month, 12th month
An effective treatment method for microcirculatory dysfunction targets in acute ischemic stroke.
Record the medication treatment information during the follow-up period since the last visit, to explore and build an effective treatment method for microcirculatory dysfunction targets in acute ischemic stroke.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The drug treatment of ischemic stroke in the recovery period based on microcirculation disorders in the real world.
Record the medication treatment information during the follow-up period since the last visit, including antiplatelet therapy, antihypertensive therapy, lipid-lowering, hypoglycemic, vasoactive drugs, neuroprotective agents, traditional Chinese medicine, etc. Detailed records of medication types, daily dosage, and duration are required.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the pathogenesis of ischemic stroke during recovery period classified by different etiological subtypes.
Record the final diagnosis and main combined diagnosis of this enrollment event and complete blood laboratory examination, transcranial doppler ultrasound examination, physical examination and the like to ensure and evaluate the correlation between microcirculatory disorders and the pathogenesis of recovery ischemic stroke in different etiological subtypes.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the severity of ischemic stroke during recovery period.
This study will collect disease information related to microcirculatory disorders and ischemic stroke patients during recovery period to evaluate the correlation between microcirculation disorders and the severity of ischemic stroke.
Time frame: baseline, 3rd month, 12th month
An effective treatment method for microcirculatory dysfunction targets in the recovery stage of ischemic stroke.
Record the medication treatment information during the follow-up period since the last visit, to explore and build an effective treatment method for microcirculatory dysfunction targets in the recovery stage of ischemic stroke.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the outcome/prognosis of ischemic stroke during recovery period.
This study will collect disease information related to microcirculatory disorders and mRS among ischemic stroke patients during recovery period to assess the correlation between microcirculatory disorders and the outcome/prognosis of ischemic stroke during recovery period.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The drug treatment of CSVD in the real world based on microcirculation disorders.
Record the medication treatment information during the follow-up period since the last visit, including antiplatelet therapy, antihypertensive therapy, lipid-lowering, hypoglycemic, vasoactive drugs, neuroprotective agents, traditional Chinese medicine, etc. Detailed records of medication types, daily dosage, and duration are required.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the pathogenesis of different subtypes of CSVD.
Record the final diagnosis and main combined diagnosis of this enrollment event and complete blood laboratory examination, transcranial doppler ultrasound examination, physical examination and the like to ensure and evaluate the correlation between microcirculatory disorders and the pathogenesis of different subtypes of CSVD.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and the severity of CSVD.
This study will collect disease information related to microcirculatory disorders and CSVD to evaluate the correlation between microcirculation disorders and the severity of CSVD.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
Effective treatment methods for microcirculatory disorders in CSVD.
Record the medication treatment information during the follow-up period since the last visit, to explore and build an effective treatment method for microcirculatory dysfunction targets in the CSVD.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
The correlation between microcirculatory disorders and clinical symptoms of CSVD.
This study will complete and collect relevant information of clinical symptoms and microcirculatory disorders among patients with CSVD.
Time frame: baseline, 14th day, 3rd month, 6th month, 12th month, 18th month, 24th month
Plan to share: No
Start is estimated for Oct 2023; primary completion for Oct 2026, 36 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cerebral Small Vessel Diseases →